期刊
INTERNATIONAL JOURNAL OF HEMATOLOGY
卷 107, 期 1, 页码 16-30出版社
SPRINGER JAPAN KK
DOI: 10.1007/s12185-017-2373-3
关键词
Iron deficiency; Hepcidin; Iron therapy; Anemia; Heart failure
类别
资金
- Fondazione Cariverona [2014.0851]
- Veneto Region [2014-00000451]
Iron deficiency, with or without anemia, is extremely frequent worldwide, representing a major public health problem. Iron replacement therapy dates back to the seventeenth century, and has progressed relatively slowly until recently. Both oral and intravenous traditional iron formulations are known to be far from ideal, mainly because of tolerability and safety issues, respectively. At the beginning of this century, the discovery of hepcidin/ferroportin axis has represented a turning point in the knowledge of the pathophysiology of iron metabolism disorders, ushering a new era. In the meantime, advances in the pharmaceutical technologies are producing newer iron formulations aimed at minimizing the problems inherent with traditional approaches. The pharmacokinetic of oral and parenteral iron is substantially different, and diversities have become even clearer in light of the hepcidin master role in regulating systemic iron homeostasis. Here we review how iron therapy is changing because of such important advances in both pathophysiology and pharmacology.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据